Items where Author is "Fattinger, K."

2001

Rentsch, K. M. and Kullak-Ublick, G. A. and Reichel, C. and Meier, P. J. and Fattinger, K.. (2001) Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. Clinical pharmacology and therapeutics, Vol. 70, H. 3. pp. 237-246.

Kullak-Ublick, G. A. and Ismair, M. G. and Stieger, B. and Landmann, L. and Huber, R. and Pizzagalli, F. and Fattinger, K. and Meier, P. J. and Hagenbuch, B.. (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, Vol. 120, H. 2. pp. 525-533.

Fattinger, K. and Funk, C. and Pantze, M. and Weber, C. and Reichen, J. and Stieger, B. and Meier, P. J.. (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump : a potential mechanism for hepatic adverse reactions. Clinical pharmacology and therapeutics, Vol. 69, H. 4. pp. 223-231.

2000

Stieger, B. and Fattinger, K. and Madon, J. and Kullak-Ublick, G. A. and Meier, P. J.. (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, Vol. 118, H. 2. pp. 422-430.

Fattinger, K. and Roos, M. and Vergères, P. and Holenstein, C. and Kind, B. and Masche, U. and Stocker, D. N. and Braunschweig, S. and Kullak-Ublick, G. A. and Galeazzi, R. L. and Follath, F. and Gasser, T. and Meier, P. J.. (2000) Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. British journal of clinical pharmacology, Vol. 49, no. 2. pp. 158-167.

Fattinger, K. and Cattori, V. and Hagenbuch, B. and Meier, P. J. and Stieger, B.. (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology, Vol. 32, No. 1. pp. 82-86.

Dürr, D. and Stieger, B. and Kullak-Ublick, G. A. and Rentsch, K. M. and Steinert, H. C. and Meier, P. J. and Fattinger, K.. (2000) St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clinical pharmacology and therapeutics, Vol. 68, H. 6. pp. 598-604.